(VIANEWS) – WALLENIUS WILHELMS (WAWI.OL), SPAREBANK 1 SMN (MING.OL), BAKKAFROST (BAKKA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. WALLENIUS WILHELMS (WAWI.OL)
1027.3% sales growth and 25.2% return on equity
Wallenius Wilhelmsen ASA, together with its subsidiaries, engages in the logistics and transportation business worldwide. It operates through three segments: Shipping Services, Logistics Services, and Government Services. The company provides liner services through a fleet of modern and versatile RoRo vessels, which carry a mix of products, such as auto, construction, mining, agriculture machinery, and breakbulk products. In addition, it offers inland transportation services, as well as operates vehicle and equipment processing centers and inland distribution networks. The company serves agriculture, automotive, aviation, boats and yachts, breakbulk, commercial vehicles, construction, machinery and machine tools, mining, oil and gas, power and energy, and rail industries. It operates approximately 125 vessels servicing 15 trade routes, 66 processing centers, and 8 marine terminals. Wallenius Wilhelmsen ASA was founded in 1861 and is based in Lysaker, Norway.
Earnings Per Share
As for profitability, WALLENIUS WILHELMS has a trailing twelve months EPS of kr21.68.
PE Ratio
WALLENIUS WILHELMS has a trailing twelve months price to earnings ratio of 4.91. Meaning, the purchaser of the share is investing kr4.91 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.2%.
Yearly Top and Bottom Value
WALLENIUS WILHELMS’s stock is valued at kr106.40 at 22:20 EST, way under its 52-week high of kr123.50 and way above its 52-week low of kr68.90.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 25, 2024, the estimated forward annual dividend rate is 12.35 and the estimated forward annual dividend yield is 12.31%.
More news about WALLENIUS WILHELMS.
2. SPAREBANK 1 SMN (MING.OL)
14.4% sales growth and 14.9% return on equity
SpareBank 1 SMN, together with its subsidiaries, provides various banking, accounting, and real estate products and services to private individuals and companies in Norway and internationally. The company offers mortgage, vehicle, green, move, consumer and other loans; refinancing; and placement, group, savings, business, group, tax deduction, currency, and deposit accounts. It also provides BSU house savings for young people; fixed interest deposits; savings and investments; cash services; and payments. In addition, the company offers car, home, personal, animal, vehicle, and travel insurance services; property buying and selling advisory services; and mobile and online banking, and various cards. Further, it offers loans for car, vehicles, and trailers, bank guarantees, business and construction loans, operating credit for agriculture, factoring, leasing, and overdrafts; various pension products; and business and personal insurance products. Additionally, the company provides documentary collection, letter of credit, forward contracts, and foreign currency account services; and accounting, HR services, taxes and duties, transactional advice, and IT solutions services. It offers money transfer, capital and investment management, advisory, interest rate and currency hedging, and investment of surplus liquidity services. SpareBank 1 SMN was founded in 1823 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, SPAREBANK 1 SMN has a trailing twelve months EPS of kr17.98.
PE Ratio
SPAREBANK 1 SMN has a trailing twelve months price to earnings ratio of 8.72. Meaning, the purchaser of the share is investing kr8.72 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.9%.
Volume
Today’s last reported volume for SPAREBANK 1 SMN is 37399 which is 54.32% below its average volume of 81881.
More news about SPAREBANK 1 SMN.
3. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through seven segments: Fishmeal, Fish Oil and Fish Feed; Freshwater FO; Freshwater SCT; Farming FO; Farming SCT; Services; and Sales & Other. The company's products include fresh and frozen whole salmon, fresh and frozen salmon fillets, fresh skin-packed salmon portions, frozen salmon portions and tails, frozen smoked salmon and salmon fillets, frozen salmon bits and pieces, frozen salmon off-cuts and belly flaps, frozen salmon heads, salmon backbones, and salmon skin under the Bakkafrost, 18 ISLANDS, HEIMLAND, BAKKA SALMON, NATIVE HEBRIDEAN, and LOCHLANDER brands. It is also involved in the production and sale of fishmeal, fish oil, and fish feed; production of eggs from breeding self-owned salmon strains; production of smolts; and on-growing of salmon. In addition, the company manages a fleet of farming service vessels; provides fish transportation, treatments, net cleaning, harvesting, freight ans logistical, and heavy marine support services; converts organic waste into biogas, heating, electricity, and fertilizers; produces styrofoam boxes; and optimizes the value creation and retention from the harvested fish. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr23.92.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 24.29. Meaning, the purchaser of the share is investing kr24.29 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 2, 2023, the estimated forward annual dividend rate is 15.63 and the estimated forward annual dividend yield is 2.69%.
Moving Average
BAKKAFROST’s worth is below its 50-day moving average of kr623.15 and below its 200-day moving average of kr629.09.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 7.54B for the twelve trailing months.
More news about BAKKAFROST.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Sales Growth
SANOFI’s sales growth for the next quarter is 7.4%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 5.2% and positive 0.8% for the next.
More news about SANOFI.
